抗肿瘤药物热门靶点研究进展

Advances in the targets of the anticancer drugs

肿瘤治疗是人类致力攻克的难题之一,近年来靶向药物正以其低毒副作用、疗效强、特异性较高等优点成为抗肿瘤药物研发的主流,但抗肿瘤靶向药物仍然存在停研率高、靶点重复、基础研究不深入、创新性不足等问题,本文分类阐述了传统抗肿瘤药物、激酶抑制剂、免疫检查点阻滞剂、组蛋白去乙酰化酶抑制剂、聚ADP核糖聚合酶抑制剂等的作用靶点及获批、在研药物的情况,以期为靶向药物研发提供思路。

Tumor therapy is one of the most challenging problems that human beings are trying to over- come. In recent years, targeted drugs have become hotspots because of its advantages, for instance, low tox- icity, strong efficacy and high specificity. However, there are still some problems such as high failure rate, repetition of target, lack of basic research and insufficient innovation. In this review, we summarize the targets and the corresponding drugs that are approved or in research, divided into traditional anti-tumor drugs, kinase inhibitors, immune checkpoint inhibitors, histone deacetylases inhibitors, poly ADP-ribose polymerase, et al. We hope to provide ideas for targeted drug research and development.